Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Arrowhead Pharma (ARWR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,349,252
  • Shares Outstanding, K 92,225
  • Annual Sales, $ 16,140 K
  • Annual Income, $ -54,450 K
  • 36-Month Beta 1.96
  • Price/Sales 83.59
  • Price/Cash Flow N/A
  • Price/Book 13.52

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 0.76
  • Number of Estimates 4
  • High Estimate 1.67
  • Low Estimate 0.38
  • Prior Year -0.18
  • Growth Rate Est. (year over year) +522.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.41 +39.48%
on 12/24/18
15.28 -4.97%
on 01/11/19
+0.79 (+5.75%)
since 12/18/18
3-Month
10.41 +39.48%
on 12/24/18
16.09 -9.76%
on 11/08/18
+1.17 (+8.76%)
since 10/18/18
52-Week
4.77 +204.40%
on 02/13/18
22.39 -35.15%
on 09/06/18
+8.80 (+153.85%)
since 01/18/18

Most Recent Stories

More News
Arrowhead Pharmaceuticals Begins Dosing in Phase 1 Study of ARO-ANG3 for Treatment of Dyslipidemias and Metabolic Diseases

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1 clinical study of ARO-ANG3, an RNAi-based investigational medicine targeting...

ARWR : 14.52 (-0.75%)
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-APOC3 for Treatment of Hypertriglyceridemia

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has filed an application for approval to begin a Phase 1 clinical trial of ARO-APOC3, an RNAi-based investigational medicine...

ARWR : 14.52 (-0.75%)
Downtrend Call Working As Arrowhead Pharma Stock Falls 27.3% (ARWR)

SmarTrend identified a Downtrend for Arrowhead Pharma (NASDAQ:ARWR) on October 5th, 2018 at $15.05. In approximately 3 months, Arrowhead Pharma has returned 27.28% as of today's recent price of $10.95....

ARWR : 14.52 (-0.75%)
Relatively Good Performance Detected in Shares of Arrowhead Pharma in the Biotechnology Industry (ARWR, PTLA , DVAX , ARRY , EXAS )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

ARWR : 14.52 (-0.75%)
DVAX : 12.05 (-0.33%)
PTLA : 26.53 (+3.59%)
Today's Research Reports on Trending Tickers: Arrowhead Pharmaceuticals and Agios Pharmaceuticals

NEW YORK, NY / ACCESSWIRE / December 12, 2018 / U.S. equities finished lower on Tuesday after bouncing between the red and green territory. The stocks gained more than 1% across the board on improving...

ARWR : 14.52 (-0.75%)
Arrowhead Pharmaceuticals Reports Fiscal 2018 Year End Results

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2018 fourth quarter and year ended September 30, 2018. The company is hosting a conference call...

ARWR : 14.52 (-0.75%)
J&J Strikes Deal with argenx to Co-Develop Cancer Antibody

Johnson & Johnson (JNJ) inks a global deal with Europe's argenx to jointly develop and globally commercialize the latter's prospective antibody, cusatuzumab.

CELG : 86.27 (-0.37%)
ARWR : 14.52 (-0.75%)
JNJ : 130.69 (+1.24%)
BMY : 50.12 (+1.05%)
Acadia Pharmaceu has the Best Relative Performance in the Biotechnology Industry (ACAD , ARWR, LXRX , NTRA , EXAS )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

LXRX : 5.96 (-22.60%)
ARWR : 14.52 (-0.75%)
ACAD : 21.07 (-2.36%)
Arrowhead Pharmaceuticals to Webcast 2018 Fiscal Year End Results

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on December 11, 2018, at 4:30 p.m. EST to discuss its financial results for the...

ARWR : 14.52 (-0.75%)
18.3% Return Seen to Date on SmarTrend Arrowhead Pharma Call (ARWR)

SmarTrend identified a Downtrend for Arrowhead Pharma (NASDAQ:ARWR) on October 5th, 2018 at $15.05. In approximately 2 months, Arrowhead Pharma has returned 18.27% as of today's recent price of $12.30....

ARWR : 14.52 (-0.75%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More Share

Trade ARWR with:

Business Summary

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes....

See More

Key Turning Points

2nd Resistance Point 15.39
1st Resistance Point 14.95
Last Price 14.52
1st Support Level 14.09
2nd Support Level 13.67

See More

52-Week High 22.39
Fibonacci 61.8% 15.66
Last Price 14.52
Fibonacci 50% 13.58
Fibonacci 38.2% 11.50
52-Week Low 4.77

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar